Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group

Journal of Clinical Oncology

Volumn 22, Issue 11, 2004, Pages 2122-2132

  Kaufman, Howard L ^a   Wang, Wei ^a   Manola, Judith ^a   DiPaola, Robert S ^a   Ko, Yoo Joung ^a   Sweeney, Christopher ^a   Whiteside, Theresa L ^a   Schlom, Jeffrey ^a   Wilding, George ^a   Weiner, Louis M ^a  

^a Och Spine at New York Presbyterian Hospitals

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; PROSTATE SPECIFIC ANTIGEN; VACCINIA ANTIBODY; VACCINIA VACCINE; VIRUS VACCINE;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FOWLPOX VIRUS; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VACCINIA VIRUS; AGED; BLOOD; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; IMMUNOLOGY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; UNITED STATES;

AGED; AGED, 80 AND OVER; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 2942644684     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.083     Document Type: Article

References (34)

1. Dawson NA: Treatment of progressive metastatic prostate cancer. Oncology 7:17-24, 1993
2. Partin AW, et al: The use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-114, 1993
3. Han M, Partin AW, Pound CR, et al: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-565, 2001
4. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
5. Sandler HM, Dunn RL, McLaughlin PW, et al: Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 48:629-633, 2000
6. Balk SP, Ko YJ, Bubley GJ: Biology of prostate-specific antigen. J Clin Oncol 21:383-391, 2003
7. Papsidero LD, Kuriyama M, Wang MC, et al: Prostate antigen: A marker for human prostate epithelial cells. J Natl Cancer Inst 66:37-42, 1981
8. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991
9. Stamey TA, McNeal JE, Yemoto CM, et al: Biological determinants of cancer progression in men with prostate cancer. JAMA 281:1395-1400, 1999
10. Riegman PH, Vlietstra RJ, Suurmeijer L, et al: Characterization of the human kallikrein locus. Genomics 14:6-11, 1992
11. Linton KD, Hamdy FC: Early diagnosis and surgical management of prostate cancer. Cancer Treat Rev 29:151-160, 2003
12. Cantalona WJ, Smith DS, Ratliff L, et al: Measurement of Prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156-1161, 1991
13. Correale P, Walmsley K, Nieroda C, et al: In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 89: 293-300, 1997
14. Alexander RB, Brady F, Leffell MS, et al: Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology 51:150-157, 1998
15. Corman JM, Sercarz EE, Nanda NK: Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol 114:166-172, 1998
16. Correale P, Walmsley K, Zaremba S, et al: Generation of human cyiolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 161:3186-3194, 1998
17. Eder JP, Kantoff PW, Roper K, et al: A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6:1632-1638, 2000
18. Hodge JW, Schlom J, Donohue SJ, et al: A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 63:231-237, 1995
19. Sanda MG, Smith DC, Charles LG, et al: Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53:260-266, 1999
20. Gulley J, Chen AP, Dahut W, et al: Phase 1 study of vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53:109-117, 2002
21. Hodge JW, McLaughlin JP, Kantor JA, et al: Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15: 759-768, 1997
22. Marshall JL, Hoyer RJ, Toomey MA, et al: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anticarcinoembryonic antigen immune responses. J Clin Oncol 18:3964-3973, 2000
23. Paoletti E: Applications of pox virus vectors to vaccination: An update. Proc Natl Acad Sci U S A 93:11349-11353, 1996
24. Horig H, Lee DS, Conkright W, et al: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 49:504-514, 2000
25. 264-272 peptide in cancer patients-implications for immunoselection of epitope-loss variants. J Immunol 165:5938-5944, 2000
26. Asai T, Storkus WJ, Whiteside TL: Evaluation of the modified ELISPOT assay for interferon-γ production in monitoring of cancer patients receiving anti-tumor vaccines. Clin Diagn Lab Immunol 7:145-154, 2000
27. Patel A, Dorey F, Franklin J, et al: Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158:1441-1445, 1997
28. D'Amico AV, Moul JW, Carroll PR, et al: Surrogate endpoint for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003
29. Verbel DA, Heller G, Kelly WK, et al: Quantifying the amount of variation in survival explained by prostate-specific antigen. Clin Cancer Res 8:2576-2579, 2002
30. Pinover WH, Horwitz EM, Hanlon AL, et al: Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 97:1127-1133, 2003
31. Roberts SG, Blute ML, Bergstralh EJ, et al: PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76:576-581, 2001
32. Scher HI, Eisenberger M, D'Amico AV, et al: Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the prostate-specific antigen working group. J Clin Oncol 22:537-556, 2004
33. Meidenbauer N, Harris DT, Spitler LE, et al: Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43:88-100, 2000
34. Dunn GP, Bruce AT, Ikeda H, et al: Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 3:991-998, 2002